The US-China biotech betting the future of obesity treatment is a pill, not an injection.
CORXEL PharmaceuticalsThe corporate wordmark, as used in its January 2026 financing announcement - a study in restraint for a company chasing one of medicine's loudest markets.
The drugs that reshaped obesity and diabetes care arrived in syringes. CORXEL Pharmaceuticals is wagering that the next chapter arrives in a tablet. Founded in 2019 as JiXing Pharmaceuticals and backed from the start by the healthcare specialist RTW Investments, the company has rebuilt itself into a globally-minded developer of cardiometabolic therapies with a name to match its ambition.
At its center is CX11, an investigational oral small-molecule GLP-1 receptor agonist aimed at obesity, overweight, and type 2 diabetes. The pitch is straightforward: match the mechanism that made injectable GLP-1 drugs a phenomenon, but deliver it as a once-daily pill - no needle, no cold chain, less friction between prescription and patient.
CORXEL is not a single-asset story. Alongside CX11 sit JX10, a thrombolytic and anti-inflammatory agent for acute ischemic stroke, and JX09, a highly selective aldosterone synthase inhibitor for hypertension. Together they trace the full arc of cardiometabolic disease - weight, blood sugar, blood pressure, and the strokes that can follow when those go unmanaged.
In January 2026 the company completed a Series D1 financing of up to $287 million, drawing a syndicate of blue-chip investors and pushing total funding to roughly $449 million. Headquartered in Berkeley Heights, New Jersey, with operations in Shanghai, CORXEL runs CX11 through a Phase 2 trial in the US and a Phase 3 trial in China at the same time.
It does all of this with about 60 people - a lean operation that puts most of its capital into the science rather than the org chart, and leans on licensing and partnerships to assemble a pipeline that would take most startups far longer to build.
This investment is one of the most significant milestones for CORXEL since its founding - it not only fuels our effort to accelerate the global development of industry-leading therapies against cardiometabolic diseases but also propels the company to a new orbit of growth.
It develops medicines for cardiometabolic disease - a cluster of conditions spanning obesity, type 2 diabetes, hypertension, and stroke. As a clinical-stage company, its work is research and trials: proving that its candidates are safe and effective before they can reach patients.
Ultimately, patients living with some of the most common chronic conditions on earth, and the clinicians who treat them. Immediately, its stakeholders are investors, trial sites, regulators, and the pharma partners who may one day help commercialize its drugs.
Injectable GLP-1 drugs work - but needles, cost, and cold-chain logistics limit who takes them and for how long. CX11 targets that friction with an oral option. JX10 and JX09 address stroke and hypertension, where treatment options remain limited.
Cardiometabolic drug development across two continents. The team pairs deep multinational-pharma experience with a deal-driven model - in-licensing differentiated assets, then running the clinical programs to prove them out in both US and Chinese trials.
Obesity · Stroke · Hypertension
An investigational oral small-molecule GLP-1 receptor agonist designed for once-daily dosing, aiming to overcome the practical limits of injectable GLP-1 therapies. Ex-China rights licensed from Vincentage.
Phase 2 US · Phase 3 ChinaA thrombolytic and anti-inflammatory agent in development for acute ischemic stroke - one of medicine's most time-critical emergencies, where treatment windows are measured in hours.
Clinical DevelopmentA highly selective aldosterone synthase inhibitor targeting hypertension, addressing blood pressure through a mechanism distinct from mainstay therapies.
Clinical DevelopmentPrior-round figure is implied from total funding and is approximate.
The Series D1 proceeds fund CX11's US Phase 2 and a planned global Phase 2 in type 2 diabetes, plus early prep for Phase 3 - alongside the stroke and hypertension programs. The round drew a syndicate that reads like a roll-call of healthcare capital:
Clinical progress, disciplined execution, and a seasoned leadership team position the company for important near-term catalysts and sustained long-term value creation.
A classic clinical-stage biopharma engine: in-license or develop differentiated cardiometabolic candidates, fund them through venture and crossover capital, and create value at clinical milestones - via partnerships, out-licensing, or eventual commercialization. CX11's ex-China rights came from a 2024 license with Vincentage.
Three things: an oral GLP-1 in a market dominated by injections; a genuinely bi-continental trial strategy that runs US and China studies in parallel; and a breadth of pipeline - obesity, stroke, hypertension - unusual for a company of roughly 60 people.
CORXEL sits in the fast-moving oral GLP-1 race, competing for the same prize as pharma giants and nimble challengers alike. Its edge is not scale - it's focus, a differentiated oral asset, and a cross-border development model. In stroke and hypertension it plays against established cardiovascular developers, betting that distinct mechanisms open room where mainstay therapies fall short.
Board Executive Director and Chief Executive Officer, responsible for the full scope of business operations. She brings nearly 30 years across GSK, AstraZeneca, Xi'an Janssen, Johnson & Johnson Medical, and MSD, having led teams to launch leading brands across therapeutic areas.
Chief Financial Officer, previously CFO of Gracell Biotechnologies, where he led the company through its 2021 Nasdaq IPO, multiple financings, and its 2024 acquisition by AstraZeneca - experience aimed squarely at CORXEL's next phase of growth.
RTW Investments incubates the company to develop innovative therapies, with a focus that would sharpen toward cardiometabolic disease.
Licenses worldwide (excluding Greater China) rights to an oral small-molecule GLP-1 receptor agonist from Vincentage - the asset that anchors the pipeline.
Appoints Kevin Xie as CFO, adding public-market and M&A experience from Gracell Biotechnologies.
Closes a Series D1 round to push CX11 through mid- and late-stage trials and fund the wider cardiometabolic pipeline.
CORXEL is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic diseases, led by CX11 - an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes - plus programs for acute ischemic stroke (JX10) and hypertension (JX09).
Yes. It was founded in 2019 as JiXing Pharmaceuticals and later rebranded to CORXEL to reflect its global cardiometabolic focus.
CORXEL raised up to $287 million in its January 2026 Series D1 round, bringing total funding to roughly $449 million across its history.
Sandy Mou, MD, is CEO and Board Executive Director, with nearly 30 years of pharmaceutical and medical-device experience. Kevin Xie serves as Chief Financial Officer.
CORXEL is headquartered in Berkeley Heights, New Jersey, with operations in China including Shanghai and Beijing, and runs clinical trials in both the US and China.
No official CORXEL interview or product-demo video was confirmed at publication. These searches surface the most relevant public material.
Compiled from public sources including company announcements and biotech trade press, current as of July 2026. Figures such as prior-round funding are approximate. Nothing here is investment or medical advice; CX11, JX10 and JX09 are investigational and not approved for use.